Other News To Note
• DiaMedica Inc., of Winnipeg, Manitoba, reported results of a preclinical study in Type I diabetes showing that chronic administration of lead compound DM-199 delayed the autoimmune attack, preserved beta cell mass and demonstrated a 12-fold increase in circulating C-peptide levels – the primary endpoint in most Type I diabetes trials – in the non-obese diabetic animal model. The increase in C-peptide levels reflected improved insulin secretion and suggested the ability of DM-199 to stabilize and preserve C-peptide in peripheral blood, according to the company.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST